HSHaolun Shi

Haolun Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haolun Shi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes

    by Yichen Yan, Ruitao Lin, Tianyu Guan, Haolun Shi, Xiaolei Lin

    Pursuing accurate observations and rational assumptions always drives advances in clinical trial design. In recent years, more trials have begun to collect multi‐graded outcomes for more informative analyses. At the same time, assumptions other than the traditional monotonicity relationship have been considered in the dose‐efficacy curve to be more realistic. Inspired by these two trends, we propose a phase I/II design that simultaneously considers multi‐categorical toxicity and efficacy with multi‐graded outcomes, measured as quasi‐continuous probability based on prespecified weight matrices of clinical significance. Following keyboard design, our approach aims to screen out overly toxic doses by the toxicity probability intervals and adaptively makes dose escalation or de‐escalation decisions by comparing the posterior distributions of dose desirability (utility) among the adjacent levels of the current dose. It helps to more accurately identify the OBD in a non‐monotonically increasing dose‐efficacy relationship. We also comprehensively present the safety, accuracy and reliability performance through numerical simulations in multiple scenarios and compare the results with several already available designs. The benchmarking results of multiple operating characteristics convincingly support that our design leads in overall performance while ensuring robustness.

  • Bayesian single‐to‐double arm transition design using both short‐term and long‐term endpoints

    by Tianlin Xu, Haolun Shi, Ruitao Lin

    The choice between single‐arm designs versus randomized double‐arm designs has been contentiously debated in the literature of phase II oncology trials. Recently, as a compromise, the single‐to‐double arm transition design was proposed, combining the two designs into one trial over two stages. Successful implementation of the two‐stage transition design requires a suspension period at the end of the first stage to collect the response data of the already enrolled patients. When the evaluation of the primary efficacy endpoint is overly long, the between‐stage suspension period may unfavorably prolong the trial duration and cause a delay in treating future eligible patients. To accelerate the trial, we propose a Bayesian single‐to‐double arm design with short‐term endpoints (BSDS), where an intermediate short‐term endpoint is used for making early termination decisions at the end of the single‐arm stage, followed by an evaluation of the long‐term endpoint at the end of the subsequent double‐arm stage. Bayesian posterior probabilities are used as the primary decision‐making tool at the end of the trial. Design calibration steps are proposed for this Bayesian monitoring process to control the frequentist operating characteristics and minimize the expected sample size. Extensive simulation studies have demonstrated that our design has comparable power and average sample size but a much shorter trial duration than conventional single‐to‐double arm design. Applications of the design are illustrated using two phase II oncology trials with binary endpoints.


  • Cost-Sensitive Learning for Medical Insurance Fraud Detection With Temporal Information

    by Haolun Shi, Mohammad A. Tayebi, Jian Pei, Jiguo Cao

    Fraudulent activities within the U.S. healthcare system cost billions of dollars each year and harm the wellbeing of many qualifying beneficiaries. The implementation of an effective fraud detection method has become imperative to secure the welfare of the general public. In this paper, we focus on the problem of fraud detection using the current year's Medicare claims data from the perspective of utilizing temporal information from the previous years. We group the data into temporal trajectories of the key covariates and base our feature engineering around these trajectories. For effective feature engineering on the temporal data, we propose to use the functional principal component analysis (FPCA) method for analyzing the temporal covariates' trajectory as well as the distributional FPCA for extracting features from the empirical probability density curve of the covariates. Moreover, we introduce the framework of cost-sensitive learning for analyzing the Medicare database to allow for asymmetrical losses in the confusion matrix, such that the classification rule reflects the realistic tradeoff between the fixed cost and the fraud cost. The issue of class imbalance in the database is tackled through the random undersampling scheme. Our results confirm that the trained classifier has a reasonably good prediction performance and a significant percentage of cost savings can be achieved by taking into account the financial cost.


  • Dynamic prediction with time‐dependent marker in survival analysis using supervised functional principal component analysis

    by Haolun Shi, Shu Jiang, Jiguo Cao

    Time-varying biomarkers reflect important information on disease progression over time. Dynamic prediction for event occurrence on a real-time basis, utilizing time-varying information, is crucial in making accurate clinical decisions. Functional principal component analysis (FPCA) has been widely adopted in the literature for extracting features from time-varying biomarker trajectories. However, feature extraction via FPCA is conducted independent of the time-to-event response, which may not produce optimal results when the goal lies in prediction. With this consideration, we propose a novel supervised FPCA, where the functional principal components are determined to optimize the association between the time-varying biomarker and time-to-event outcome. The proposed framework also accommodates irregularly spaced and sparse longitudinal data. Our method is empirically shown to retain better discrimination and calibration performance than the unsupervised FPCA method in simulation studies. Application of the proposed method is also illustrated in the Alzheimer's Disease Neuroimaging Initiative database.


  • Open Access

    Jointly modelling multiple transplant outcomes by a competing risk model via functional principal component analysis

    by Jianghu (James) Dong, Haolun Shi, Liangliang Wang, Ying Zhang, Jiguo Cao

    In many clinical studies, longitudinal biomarkers are often used to monitor the progression of a disease. For example, in a kidney transplant study, the glomerular filtration rate (GFR) is used as a longitudinal biomarker to monitor the progression of the kidney function and the patient's state of survival that is characterized by multiple time-to-event outcomes, such as kidney transplant failure and death. It is known that the joint modelling of longitudinal and survival data leads to a more accurate and comprehensive estimation of the covariates' effect. While most joint models use the longitudinal outcome as a covariate for predicting survival, very few models consider the further decomposition of the variation within the longitudinal trajectories and its effect on survival. We develop a joint model that uses functional principal component analysis (FPCA) to extract useful features from the longitudinal trajectories and adopt the competing risk model to handle multiple time-to-event outcomes. The longitudinal trajectories and the multiple time-to-event outcomes are linked via the shared functional features. The application of our model on a real kidney transplant data set reveals the significance of these functional features, and a simulation study is carried out to validate the accurateness of the estimation method.


  • uTPI: A utility‐based toxicity probability interval design for phase I/II dose‐finding trials

    by Haolun Shi, Jiguo Cao, Ying Yuan, Ruitao Lin

    Unlike chemotherapy, the maximum tolerated dose (MTD) of molecularly targeted agents and immunotherapy may not pose significant clinical benefit over the lower doses. By simultaneously considering both toxicity and efficacy endpoints, phase I/II trials can identify a more clinically meaningful dose for subsequent phase II trials than traditional toxicity‐based phase I trials in terms of risk‐benefit tradeoff. To strengthen and simplify the current practice of phase I/II trials, we propose a utility‐based toxicity probability interval (uTPI) design for finding the optimal biological dose, based on a numerical utility that provides a clinically meaningful, one‐dimensional summary representation of the patient's bivariate toxicity and efficacy outcome. The uTPI design does not rely on any parametric specification of the dose‐response relationship, and it directly models the dose desirability through a quasi binomial likelihood. Toxicity probability intervals are used to screen out overly toxic dose levels, and then the dose escalation/de‐escalation decisions are made adaptively by comparing the posterior desirability distributions of the adjacent levels of the current dose. The uTPI design is flexible in accommodating various dose desirability formulations, while only requiring minimum design parameters. It has a clear decision structure such that a dose‐assignment decision table can be calculated before the trial starts and can be used throughout the trial, which simplifies the practical implementation of the design. Extensive simulation studies demonstrate that the proposed uTPI design yields desirable as well as robust performance under various scenarios.


  • Open Access

    Demystify Lindley's Paradox by Interpreting P-value as Posterior Probability

    by Guosheng Yin, Haolun Shi

    In the hypothesis testing framework, p-value is often computed to determine rejection of the null hypothesis or not. On the other hand, Bayesian approaches typically compute the posterior probability of the null hypothesis to evaluate its plausibility. We revisit Lindley's paradox (Lindley, 1957) and demystify the conflicting results between Bayesian and frequentist hypothesis testing procedures by casting a two-sided hypothesis as a combination of two one-sided hypotheses along the opposite directions. This can naturally circumvent the ambiguities of assigning a point mass to the null and choices of using local or non-local prior distributions. As p-value solely depends on the observed data without incorporating any prior information, we consider non-informative prior distributions for fair comparisons with p-value. The equivalence of p-value and the Bayesian posterior probability of the null hypothesis can be established to reconcile Lindley's paradox. Extensive simulation studies are conducted with multivariate normal data and random effects models to examine the relationship between the p-value and posterior probability.